-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $43

Benzinga·05/08/2026 13:27:49
Listen to the news
Guggenheim analyst Debjit Chattopadhyay maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $52 to $43.